業績紹介

2017年 論文

  • Vasohibin-1 as a novel microenvironmental biomarker for patient risk reclassification in low-risk prostate cancer.
    Kobayashi H, Kosaka T, Mikami S, Miyazaki Y, Matsumoto K, Kikuchi E, Miyajima A, Kameyama K, Sato Y, Oya M.
    Oncotarget. 2017 Dec 7;9(12):10203-10210. doi: 10.18632/oncotarget.23011. eCollection 2018 Feb 13.
  • Vasohibin-1 as a novel microenvironmental biomarker for patient risk reclassification in low-risk prostate cancer.
    Kobayashi H, Kosaka T, Mikami S, Miyazaki Y, Matsumoto K, Kikuchi E, Miyajima A, Kameyama K, Sato Y, Oya M.
    Oncotarget. 2017 Dec 7;9(12):10203-10210
  • Can urologists introduce the concept of "oligometastasis" for metastatic bladder cancer after total cystectomy?
    Ogihara K, Kikuchi E, Watanabe K, Kufukihara R, Yanai Y, Takamatsu K, Matsumoto K, Hara S, Oyama M, Monma T, Masuda T, Hasegawa S, Oya M.
    Oncotarget. 2017 Dec 4;8(67):111819-111835.
  • The preoperative sarcopenia status is associated with lymphovascular invasion in upper tract urothelial carcinoma patients treated with radical nephroureterectomy.
    Anno T, Kikuchi E, Fukumoto K, Ogihara K, Oya M.
    Can Urol Assoc J. 2017 Dec 22. doi: 10.5489/cuaj.4786.
  • Pre-operative and post-operative estimated glomerular filtration rate in Japanese patients with urological malignancies.
    Niwa N, Yoshida T, Mizuno R, Kikuchi E, Miyajima A, Hayashi M, Oya M.
    Clin Exp Nephrol. 2017 Nov 27. doi: 10.1007/s10157-017-1509-3.
  • Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer.
    Kosaka T, Hongo H, Miyazaki Y, Nishimoto K, Miyajima A, Oya M.
    Oncotarget. 2017 Sep 21;8(50):87675-87683. doi: 10.18632/oncotarget.21147. eCollection 2017 Oct 20.
  • Significance of a frozen section analysis of the ureteral margin in bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapy.
    Hakozaki K, Kikuchi E, Fukumoto K, Shirotake S, Miyazaki Y, Maeda T, Kaneko G, Yoshimine S, Tanaka N, Kanai K, Oyama M, Nakajima Y, Momma T, Oya M.
    Med Oncol. 2017 Oct 23;34(12):187.
  • Ra-223 SPECT for semi-quantitative analysis in comparison with Tc-99m HMDP SPECT: phantom study and initial clinical experience.
    Owaki Y, Nakahara T, Kosaka T, Fukada J, Kumabe A, Ichimura A, Murakami M, Nakajima K, Fukushi M, Inoue K, Oya M, Jinzaki M.
    EJNMMI Res. 2017 Oct 3;7(1):81.
  • Obstructive azoospermia caused by low ligation of varicocele: A case report.
    Hagiuda J, Ishikawa H, Hagiwara M, Kono H, Nakagawa K, Oya M.
    Syst Biol Reprod Med. 2017 Oct;63(5):338-339.
  • Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma.
    Mizuno R, Kimura G, Fukasawa S, Ueda T, Kondo T, Hara H, Shoji S, Kanao K, Nakazawa H, Tanabe K, Horie S, Oya M; Tokyo Metropolitan Study Group.
    Cancer Sci. 2017 Sep;108(9):1858-1863.
  • The Conditional Survival with Time of Intravesical Recurrence of Upper Tract Urothelial Carcinoma.
    Shigeta K, Kikuchi E, Hagiwara M, Ando T, Mizuno R, Abe T, Mikami S, Miyajima A, Nakagawa K, Oya M.
    J Urol. 2017 Dec;198(6):1278-1285.
  • Prognostic significance of erythrocyte protein band 4.1-like5 expression in upper urinary tract urothelial carcinoma.
    Daimon T, Kosaka T, Kikuchi E, Mikami S, Miyazaki Y, Hashimoto A, Hashimoto S, Mizuno R, Miyajima A, Okada Y, Sabe H, Oya M.
    Urol Oncol. 2017 Sep;35(9):543.e17-543.e24.
  • Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study.
    Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, Motzer RJ, Uemura H, McHenry MB, Berghorn E, Ozono S.
    Jpn J Clin Oncol. 2017 Jul 1;47(7):639-646.
  • Headache Caused by Brain Metastases of Castration-resistant Prostate Cancer during Cabazitaxel Therapy.
    Watanabe K, Kosaka T, Hongo H, Tamaki S, Oya M.
    Keio J Med. 2017 Dec 25;66(4):65-71.
  • Prolonged pneumoperitoneum time is an independent risk factor for intravesical recurrence after laparoscopic radical nephroureterectomy in upper tract urothelial carcinoma.
    Shigeta K, Kikuchi E, Hagiwara M, Ando T, Mizuno R, Miyajima A, Nakagawa K, Oya M.
    Surg Oncol. 2017 Mar;26(1):73-79.
  • Increased vasohibin-1 expression is associated with metastasis and poor prognosis of renal cell carcinoma patients.
    Mikami S, Oya M, Kosaka T, Mizuno R, Miyazaki Y, Sato Y, Okada Y.
    Lab Invest. 2017 Jul;97(7):854-862.
  • Somatic KCNJ5 mutation occurring early in adrenal development may cause a novel form of juvenile primary aldosteronism.
    Tamura A, Nishimoto K, Seki T, Matsuzawa Y, Saito J, Omura M, Gomez-Sanchez CE, Makita K, Matsui S, Moriya N, Inoue A, Nagata M, Sasano H, Nakamura Y, Yamazaki Y, Kabe Y, Mukai K, Kosaka T, Oya M, Suematsu S, Nishikawa T.
    Mol Cell Endocrinol. 2017 Feb 5;441:134-139.
  • Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study.
    Oya M, Tomita Y, Fukasawa S, Shinohara N, Habuchi T, Rini BI, Fujii Y, Kamei Y, Umeyama Y, Bair AH, Uemura H.
    Cancer Sci. 2017 Jun;108(6):1231-1239.
  • Diagnosis of Renal Angiomyolipomas: Classic, Fat-Poor, and Epithelioid Types.
    Jinzaki M, Silverman SG, Akita H, Mikami S, Oya M.
    Semin Ultrasound CT MR. 2017 Feb;38(1):37-46.
  • Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy: the Role of Ultrasensitive Prostate Specific Antigen.
    Matsumoto K, Komatsuda A, Yanai Y, Niwa N, Kosaka T, Mizuno R, Kikuchi E, Miyajima A, Oya M.
    J Urol. 2017 Mar;197(3 Pt 1):655-661.
  • Simple and practical nomograms for predicting the stone-free rate after shock wave lithotripsy in patients with a solitary upper ureteral stone.
    Niwa N, Matsumoto K, Miyahara M, Omura M, Kobayashi H, Kikuchi E, Miyajima A, Miyata K, Oya M.
    World J Urol. 2017 Sep;35(9):1455-1461.
  • Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy.
    Mizuno R, Miyajima A, Hibi T, Masuda A, Shinojima T, Kikuchi E, Jinzaki M, Oya M.
    Med Oncol. 2017 Apr;34(4):47.
  • Natural course of asymptomatic abnormal prostate findings incidentally detected by CT after intravesical BCG therapy.
    Matsushima M, Kikuchi E, Akita H, Miyajima A, Oya M, Jinzaki M.
    Int J Clin Oncol. 2017 Jun;22(3):554-562.
  • The learning curve of laparoendoscopic single-site adrenalectomy: an analysis of over 100 cases.
    Fukumoto K, Miyajima A, Hattori S, Matsumoto K, Abe T, Kurihara I, Jinzaki M, Kikuchi E, Oya M.
    Surg Endosc. 2017 Jan;31(1):170-177.
  • Characterizing intermediate-risk non-muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy.
    Matsumoto K, Kikuchi E, Yanai Y, Hayakawa N, Ito Y, Maeda T, Nagata H, Miyajima A, Oya M.
    Urol Oncol. 2017 May;35(5):208-214.
  • Novel algorithm for management of acute epididymitis.
    Hongo H, Kikuchi E, Matsumoto K, Yazawa S, Kanao K, Kosaka T, Mizuno R, Miyajima A, Saito S, Oya M.
    Int J Urol. 2017 Jan;24(1):82-87.
  • Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
    Tanaka N, Mizuno R, Yasumizu Y, Ito K, Shirotake S, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M.
    Urol Oncol. 2017 Feb;35(2):39.e19-39.e28.
  • Immunohistochemistry of aldosterone synthase leads the way to the pathogenesis of primary aldosteronism.
    Nishimoto K, Koga M, Seki T, Oki K, Gomez-Sanchez EP, Gomez-Sanchez CE, Naruse M, Sakaguchi T, Morita S, Kosaka T, Oya M, Ogishima T, Yasuda M, Suematsu M, Kabe Y, Omura M, Nishikawa T, Mukai K.
    Mol Cell Endocrinol. 2017 Feb 5;441:124-133.
業績紹介